MDT perspectives on novel approaches to overcome resistance with standard-of-care immunotherapy for non-driver mutation metastatic NSCLC
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team review novel approaches to overcome resistance to standard-of-care immunotherapy for non-driver mutation metastatic NSCLC, including new immune checkpoint inhibitor combinations and emerging novel targets.
The multidisciplinary team:
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/
Create your
podcast in
minutes
It is Free